The drugs, suvorexant-first dual orexin blocker to treat insomnia and Lemborexant (in phase-3 trials), almorexant, daridorexant, filorexant are some promising dual antagonists of orexin-OX1 and OX2 receptors associated with relieving neuropsychiatric symptoms of sleep-wake disorders and insomnia in AD [193]–[196]. The gene discussed is HCRT; the disease is Alzheimer disease.